How to buy Xencor stock - 10 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Xencor stock

Own Xencor stock in just a few minutes.

Xencor, Inc is a biotechnology business based in the US. Xencor shares (XNCR) are listed on the NASDAQ and all prices are listed in US Dollars. Xencor employs 202 staff and has a trailing 12-month revenue of around USD$122.7 million.

How to buy shares in Xencor

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Xencor. Find the stock by name or ticker symbol: XNCR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Xencor reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Xencor, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Xencor. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Xencor share price

Use our graph to track the performance of XNCR stocks over time.

Xencor shares at a glance

Information last updated 2021-04-09.
52-week rangeUSD$26.8 - USD$55.33
50-day moving average USD$45.3576
200-day moving average USD$43.9003
Wall St. target priceUSD$54.5
PE ratio 67.3913
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.607

Buy Xencor shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Xencor stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Xencor under- or over-valued?

Valuing Xencor stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Xencor's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Xencor's P/E ratio

Xencor's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 67x. In other words, Xencor shares trade at around 67x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Xencor's EBITDA

Xencor's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$27.5 million.

The EBITDA is a measure of a Xencor's overall financial performance and is widely used to measure a its profitability.

Xencor financials

Revenue TTM USD$122.7 million
Gross profit TTM USD$-47,108,000
Return on assets TTM -6.94%
Return on equity TTM -11.9%
Profit margin -56.51%
Book value $9.891
Market capitalisation USD$2.4 billion

TTM: trailing 12 months

Shorting Xencor shares

There are currently 2.9 million Xencor shares held short by investors – that's known as Xencor's "short interest". This figure is 3.2% down from 3.0 million last month.

There are a few different ways that this level of interest in shorting Xencor shares can be evaluated.

Xencor's "short interest ratio" (SIR)

Xencor's "short interest ratio" (SIR) is the quantity of Xencor shares currently shorted divided by the average quantity of Xencor shares traded daily (recently around 232886.55529037). Xencor's SIR currently stands at 12.57. In other words for every 100,000 Xencor shares traded daily on the market, roughly 12570 shares are currently held short.

However Xencor's short interest can also be evaluated against the total number of Xencor shares, or, against the total number of tradable Xencor shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xencor's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Xencor shares in existence, roughly 50 shares are currently held short) or 0.1058% of the tradable shares (for every 100,000 tradable Xencor shares, roughly 106 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Xencor.

Find out more about how you can short Xencor stock.

Xencor share dividends

We're not expecting Xencor to pay a dividend over the next 12 months.

Xencor share price volatility

Over the last 12 months, Xencor's shares have ranged in value from as little as $26.8 up to $55.33. A popular way to gauge a stock's volatility is its "beta".

XNCR.US volatility(beta: 0.67)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xencor's is 0.6691. This would suggest that Xencor's shares are less volatile than average (for this exchange).

Xencor overview

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies. It is also developing Tidutamab that is in Phase 1 clinical trial to treat neuroendocrine tumors and gastrointestinal stromal tumors; XmAb564 to treat Autoimmune diseases; XmAb819 for the treatment of renal cell carcinoma; and XmAb306/RO7310729, which is in Phase 1 clinical trial to treat solid tumors. In addition, the company provides Monjuvi for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome; and AIMab7195 to reduce blood serum levels of IgE, which mediates allergic responses and allergic disease. It has a collaboration and license agreement with Genentech, MorphoSys AG, Nestlé S.A., Novartis AG, INmune Bio, Inc., Janssen Biotech, Inc., Astellas Pharma, Inc., Amgen Inc., Atreca, Inc., and The University of Texas MD Anderson Cancer Center. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site